Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc.

CourtDistrict Court, S.D. Alabama
DecidedMarch 6, 2018
Docket1:17-cv-00053
StatusUnknown

This text of Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc. (Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Alabama primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc., (S.D. Ala. 2018).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF ALABAMA SOUTHERN DIVISION

FAMILY MEDICINE PHARMACY LLC, ) ) Plaintiff, ) ) v. ) CIVIL ACTION 17-0053-WS-MU ) IMPAX LABORATORIES, INC., ) ) Defendant. )

FINAL JUDGMENT AND ORDER APPROVING CLASS SETTLEMENT This matter comes before the Court on plaintiff’s Unopposed Motion for Final Approval of Class Action Settlement and Entry of Final Judgment (doc. 55) and plaintiff’s Motion for Award of Attorneys’ Fees, Expenses and Incentive Payments for Class Representatives (doc. 54). For the reasons set forth herein, both Motions are granted. On September 29, 2017, the undersigned entered an Order (doc. 50) granting preliminary approval (the “Preliminary Approval Order”) of the settlement reached between plaintiff, Family Medicine Pharmacy LLC (“Family Medicine”), on its own behalf and on behalf of the settlement class, and defendant, Impax Laboratories, Inc. This settlement is memorialized in a 41-page Settlement Agreement and Release attached as Exhibit 1 to plaintiff’s Memorandum in Support of Motion for Preliminary Approval of Class Action Settlement (doc. 49). Capitalized terms used herein shall have the same meanings ascribed to them in the Settlement Agreement. On March 6, 2018, the Court held a fairness hearing. Counsel for all parties attended and participated in the hearing. Members of the Settlement Class were given appropriate notice of the Fairness Hearing and were invited to attend in order to assert any objections to the terms of the Settlement Agreement or plaintiff’s requests for approval/award of attorney’s fees, class representative incentive payment and reimbursement of expenses. Pursuant to the Preliminary Approval Order and Rule 23(e), Fed.R.Civ.P., an opportunity to be heard was given to all such class members at the Fairness Hearing; however, no persons other than the parties and their counsel appeared at the Fairness Hearing, requested leave of court to address any aspect of the proposed settlement, or filed any notice, request or motion prior to the Fairness Hearing seeking an opportunity to be heard or articulating any objections to the settlement, the requested attorney’s fee award, incentive payments or expense reimbursement. The Court having considered the Settlement Agreement, plaintiff’s Memorandum Brief of Points and Authorities (doc. 56), the Motions and exhibits thereto, the Preliminary Approval Order, and the arguments and evidence presented at the Fairness Hearing, it is hereby ORDERED as follows: 1. This Court has jurisdiction over Plaintiff, Defendant, members of the Settlement Class, the Escrow Account, and the claims asserted in this action. 2. The Settlement Agreement was entered into in good faith following arm’s length negotiations, including a mediation session before an experienced mediator. 3. Pursuant to Rule 23(e), Fed.R.Civ.P., this Court grants final approval of the Settlement Agreement, including but not limited to the Releases set forth therein, and finds that the Settlement Agreement is in all respects fair, adequate and reasonable, is not the product of collusion between the parties, and is in the best interests of the Settlement Class, for the reasons set forth below.1 All members of the Settlement Class that have not opted out are bound by this Final Judgment and Order.

1 “In determining whether the class action settlement is fair, reasonable, and adequate, the district court considers these factors: (1) the likelihood of success at trial; (2) the range of possible recovery; (3) the point on or below the range of possible recovery at which a settlement is fair, adequate and reasonable; (4) the complexity, expense and duration of litigation; (5) the substance and amount of opposition to the settlement; and (6) the stage of proceedings at which the settlement was achieved.” Nelson v. Mead Johnson & Johnson Co., 484 Fed.Appx. 429, 434 (11th Cir. 2012) (citing Bennett v. Behring Corp., 737 F.2d 982, 986 (11th Cir. 1984)). Those factors support a conclusion that the settlement achieved in this case is fair, reasonable and adequate. In particular, plaintiff’s success at trial was by no means a foregone conclusion. The types of risks that class members would have faced had the litigation not settled include, without limitation, the possibility that class certification could have been denied, or that defendant’s “informational,” “consent” or “established business relationship” defenses could have been deemed meritorious. Moreover, had class members prevailed at trial, their most likely recovery would have been statutory damages of $500 per fax transmission. See 47 U.S.C. § 227(b)(3)(B) (allowing recovery of “actual monetary loss from such a violation, or … $500 in damages for each violation, whichever is greater”). After deduction of the typical plaintiff’s counsel’s one-third contingency fee (because the TCPA does not provide for a separate award of attorney’s fees for successful plaintiffs), class members would have been left with a recovery of $333.33/fax, less expenses. Under the terms of the Settlement Agreement, (Continued) CLASS CERTIFICATION 4. The class that was conditionally certified in the Preliminary Approval Order is now finally certified, solely for purposes of this Settlement, pursuant to Rule 23(a) and 23(b)(3) of the Federal Rules of Civil Procedure, to-wit: All individuals and/or entities who[] or which received one or more unsolicited advertisements via facsimile from Defendant between December 1, 2013 and the date of entry of the Preliminary Approval Order, which was September 29, 2017. 5. The Court finds that certification of the Settlement Class solely for purposes of this settlement is appropriate for the reasons set forth in detail in the Preliminary Approval Order, including the following: (a) the Settlement Class is so numerous that joinder of all members is impracticable; (b) there are questions of law and fact common to the Settlement Class that predominate over those questions affecting only individual Settlement Class Members; (c) Family Medicine’s claims are typical of the claims of the Settlement Class; (d) Family Medicine has fairly and adequately protected, and will fairly and adequately protect, the interests of the Settlement Class; (e) McFerrin Law Firm LLC and Zarzaur Mujumdar & Debrosse are adequate Settlement Class counsel; and (f) a class action is superior to other available methods for fairly and efficiently adjudicating the controversy. 6. Family Medicine is designated as Class Representative of the Settlement Class. 7. James H. McFerrin of McFerrin Law Firm LLC in Birmingham, Alabama, and Diandra S. Debrosse Zimmermann of Zarzaur Mujumdar & Debrosse in Birmingham, Alabama, are appointed as Settlement Class Counsel.

however, each Settlement Class Member receives an estimated $357.66/fax, net of attorney’s fees. (To calculate, $4,815,700.00 gross settlement - $1,600,000.00 attorney’s fees - $1,450.00 expenses - $20,000 incentive payment = $3,194,250.00 net settlement. Dividing $3,194,250.00 / 8,931 compensable faxes = $357.66 per compensable fax.) That figure exceeds the net statutory damages achievable, absent a willfulness finding that was highly doubtful and uncertain. Moreover, by settling now, the parties avoided potentially years of additional expensive litigation proceedings, including extensive discovery, summary judgment briefing, trial and appeals. The parties have proceeded far enough in the case to be able to reach a knowledgeable, informed settlement, without having invested the massive amount of additional resources necessary to prepare the case for trial.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Faught v. American Home Shield Corp.
668 F.3d 1233 (Eleventh Circuit, 2012)
In re Checking Account Overdraft Litigation
830 F. Supp. 2d 1330 (S.D. Florida, 2011)
Bennett v. Behring Corp.
737 F.2d 982 (Eleventh Circuit, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
Family Medicine Pharmacy, LLC v. Impax Laboratories, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/family-medicine-pharmacy-llc-v-impax-laboratories-inc-alsd-2018.